The University of Virginia Cancer Center Received NCI Comprehensive Designation
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
Artificial Intelligence | Biotechnology | CRISPR | Genomics | Life Science History | Life Science News | Medicine | NIH | Non-Profit Research | Therapeutics | Vaccine
Cancer MoonShot program reignited
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
Hologic added Aptima SARS-CoV-2 assay to its Global Access Initiative in resource-limited countries
On Jan 5, 2022, Hologic the addition of the Aptimaï¾® SARS-CoV-2 assay to its Global Access Initiative, a…
Eight substances added to 15th Report on Carcinogens
On Dec. 23, 2021, eight substances were added to the Report on Carcinogens, bringing the total list to…
Swedish announced transformational $20 million gift from late philanthropist Paul G. Allen
On Nov. 9, 2021, Swedish announced a $20 million personal bequest from the late philanthropist Paul G. Allen,…
Biotechnology | Diagnostics | Disease | Life Science News | Medicine | Non-Profit Research | Therapeutics
Oregon Health & Science University moved forward with hospital expansion
On Oct. 29, 2021, Oregon Health & Science University’s (OHSU) board of directors approved a project to expand…
Biotechnology | COVID-19 | HIV | Life Science History | Non-Profit Research | Polio | Therapeutics | Vaccine | WHO
WHO bestowed posthumous award on the late Henrietta Lacks
On Oct. 13, 2021, the World Health Organization (WHO) honoured the late Henrietta Lacks with a WHO Director-General’s…
the Fred & Pamela Buffett Cancer Center received NCI designated cancer center renewal
On Oct. 4, 2021, the Fred & Pamela Buffett Cancer Center announced it had successfully renewed its National…
Biotechnology | COVID-19 | Genomics | HIV | Life Science News | Vaccine
Winners of 2022 Breakthrough Prizes In Life Sciences announced
On Sept. 22, 2021, the Breakthrough Prize Foundation and its founding sponsors announced the 2022 winners of the…
City of Hope trial was first to test an investigational COVID-19 vaccine in immunocompromised bone marrow transplant
On Sept. 14, 2021, City of Hope announced that it had begun enrolling patients in a Phase 2…
Biotechnology | Diagnostics | Disease | Environmental | Genomics | Life Science News | NIH | Oncology
NIH study illuminated origins of lung cancer in never smokers
On Sept. 6, 2021, a genomic analysis of lung cancer in people with no history of smoking has…
Rapid decrease in lung cancer and melanoma deaths lead overall continued decline in cancer death rate
On Jul. 8, 2021, the National Institutes of Health (NIH) reported that the overall cancer death rates continue…
CytoDyn received first order from Chiral Pharma for use of Leronlimab for COVID-19 patients in the Philippines
On Jun. 1, 2021, CytoDyn announced that Chiral Pharma in the Philippines placed its first purchase order for…
Biotechnology | Diagnostics | Disease | FDA | Life Science News | Oncology | Radiology | Therapeutics
FDA approved LUMAKRAS for patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer
On May 28, 2021, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib)…
Roswell Park, Wilmot Cancer Institute collaborated on first large study of immunotherapy in black cancer patients
On Apr. 20, 2021, a new collaboration between Roswell Park and the Wilmot Cancer Institute was announced that…
Tonix Pharma entered worldwide licensing agreement to develop antiviral SARS-CoV-2 inhibitor for treatment of COVID-19
On Apr. 19, 2021, Tonix Pharmaceuticals and OyaGen announced an exclusive worldwide licensing agreement for an antiviral inhibitor…
FDA approved first immunotherapy for initial treatment of gastric cancer
On Apr. 16, 2021, the FDA approved Bristol-Myers Squibb’ s Opdivo (nivolumab), in combination with certain types of…
The Priestley Medal was awarded to Paul Alivisatos
On Apr. 9, 2021, the American Chemical Society awarded The Priestley Medal to Paul Alivisatos “to recognize distinguished…
FDA approved Bristol Myers Squibbï¾’s and bluebird bioï¾’s Abecma for Relapsed or Refractory Multiple Myeloma
On Mar. 26, 2021, Bristol Myers Squibb and bluebird bio announced that the FDA had approved Abecma (idecabtagene…
AIM ImmunoTech announced addition of single-agent Ampligen arm to Cancer Center’s study in cancer patients with COVID-19
On Mar. 22, 2021, AIM ImmunoTech announced that the Institutional Review Board (IRB) of Roswell Park Comprehensive Cancer…
TGen-led study confirmed cell-free DNA in urine as potential method for cancer detection
On Feb. 17, 2021, TGen, an affiliate of City of Hope announced that it had found a way…
Notch Therapeutics closed $85 million financing to develop pipeline of renewable stem cell-derived cancer immunotherapies
On Feb. 10, 2021, Notch Therapeutics closed $85 Million Series A financing to develop pipeline of renewable stem…
Patients in cancer remission at high risk for severe COVID-19 illness
On Jan. 21, 2021, Penn Medicine reported that patients with inactive cancer and not currently undergoing treatments also…
FDA conditionally approved first oral tablet to treat lymphoma in dogs
On Jan. 11, 2021, the FDA conditionally approved Anivive Lifesciences’ Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma,…
American Cancer Society reported largest one-year drop in cancer mortality from 1991-2017
On Jan. 8, 2021, the American Cancer Society reported that the death rate from cancer in the U.S….
FDA approved first oral hormone therapy for teating advanced prostate cancer
On Dec. 18, 2020, tthe U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult…
FDA approved first PSMA-targeted PET imaging drug for men with prostate cancer
On Dec. 1, 2020, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) ï¾– the first drug for…
AIM ImmunoTech announced patient dosed in study of Ampligen as combo treatment for patients with cancer and COVID-19
On Nov. 25, 2020, AIM ImmunoTech announced that Roswell Park Comprehensive Cancer Centerï¾’s Phase 1/2a study evaluating the…
BioNTech and InstaDeep announce AI Innovation Lab to develop novel immunotherapies
On Nov. 25, 2020, BioNTech and InstaDeep announced a multi-year strategic collaboration aimed at applying the latest advances…
Study of ‘exceptional responders’ yields clues to cancer and potential treatments
On Nov. 19, 2020, in a comprehensive analysis of patients with cancer who had exceptional responses to therapy,…